Third-line therapy and beyond for patients with advanced/metastatic non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Corral Jaime, Jesus [1 ]
Gonzalez de la Pena, Miriam [1 ]
Alonso, Miriam [1 ]
Sanchez Gastaldo, Amparo [1 ]
Dolores Mediano, Maria [1 ]
Amerigo, Marta [1 ]
Enrique Robles, Carlos [1 ]
机构：
[1] Hosp Univ Virgen Rocio, Seville, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19160
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    ONKOLOGIE, 2003, 26 : 26 - 32
  • [42] Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?
    Nooshin Hashemi-Sadraei
    Nathan A. Pennell
    Current Treatment Options in Oncology, 2012, 13 : 478 - 490
  • [43] Advanced Non-Small Cell Lung Cancer (NSCLC): Maintenance Therapy for All?
    Hashemi-Sadraei, Nooshin
    Pennell, Nathan A.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2012, 13 (04) : 478 - 490
  • [44] The therapy of locally advanced non-small cell lung cancer (NSCLC) in the elderly
    Schild, S. E.
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 60 : S7 - S7
  • [45] Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)
    Reck, M
    ANTICANCER RESEARCH, 2005, 25 (3A) : 1501 - 1506
  • [46] The impact of previous therapy strategy on the efficiency of anlotinib hydrochloride as a third-line treatment on patients with advanced non-small cell lung cancer (NSCLC): a subgroup analysis of ALTER0303 trial
    Wang, Lili
    He, Zhen
    Yang, Sen
    Tang, Hong
    Wu, Yufeng
    Li, Shaomei
    Han, Baohui
    Li, Kai
    Zhang, Li
    Shi, Jianhua
    Wang, Zhehai
    Cheng, Ying
    He, Jianxing
    Shi, Yuankai
    Chen, Weiqiang
    Luo, Yi
    Wu, Lin
    Wang, Xiuwen
    Nan, Kejun
    Jin, Faguang
    Dong, Jian
    Li, Baolan
    Sun, Yan
    Wang, Qiming
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (05) : 575 - +
  • [47] Third-line erlotinib therapy versus best supportive care for advanced non-small cell lung cancer (NSCLC) in British Columbia (BC), Canada. Is it cost effective?
    Melosky, Barb L.
    Taylor, Suzanne C.
    Peacock, Stuart J.
    Johnston, Karissa
    van der Hoek, Kim
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S463 - S464
  • [48] The Need for Third-line Treatment in Non-small Cell Lung Cancer: An Overview of New Options
    Syrigos, Kostas N.
    Saif, Muhammad W.
    Karapanagiotou, Eleni M.
    Oikonomopoulos, George
    De Marinis, Filippo
    ANTICANCER RESEARCH, 2011, 31 (02) : 649 - 659
  • [49] Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy
    Cartei, G.
    Binato, S.
    Sacco, C.
    Bearz, A.
    Scalone, S.
    Ceravolo, R.
    Cingarlini, S.
    Fantoni, U.
    Palamidese, A.
    Iop, A.
    Colombrino, E.
    ANNALS OF ONCOLOGY, 2006, 17 : V47 - V51
  • [50] Efficacy and Safety of Osimertinib as Third-Line or Later Therapy for T790M-Positive Advanced Non-Small Cell Lung Cancer
    Shimada, H.
    Endo, S.
    Sasahara, Y.
    Shinmura, T.
    Ozawa, T.
    Majima, H.
    Hara, T.
    Imase, R.
    Yamauchi, S.
    Sakakibara, Y.
    Kobayashi, A.
    Yamazaki, K.
    Jin, Y.
    Yamanaka, K.
    Matsubara, O.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2138 - S2139
12345